#InTheNews: "#Bioengineering is really the way we have to move forward. We must seize this opportunity to merge these disciplines and drive innovation. The power of data and #technology is transforming biology, and now is the time for us to leverage these tools to shape a future that addresses some of the world’s most pressing issues. This is our moment to lead the way in this new era of science." Kiran Mazumdar Shaw at the #BTS2024. https://lnkd.in/eMj34cki
Biocon
Biotechnology Research
Bangalore, Karnataka 864,580 followers
About us
Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.
- Website
-
http://www.biocon.com
External link for Biocon
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Bangalore, Karnataka
- Type
- Public Company
Locations
-
Primary
Hosur Road, Electronics City
Bangalore, Karnataka 560100, IN
Employees at Biocon
Updates
-
Biocon at #CPHIIndia! Meet us at #CPHIIndia! We look forward to meeting our customers and partners to share our latest product developments, services, and portfolio. To book a meeting, write to us at: For API: contactus.API@biocon.com For Generic Formulations: contactus.formulations@biocon.com
-
"What truly inspires me are the startups bringing innovative ideas to life, taking them to market, and scaling them with passion and determination. It’s incredible to see these cool ideas transform into successful ventures. I’m deeply excited by new technologies and even more inspired by the extraordinary talent pool we have in our city - bright young minds brimming with creativity and potential. It’s this convergence of innovation and talent that fuels my optimism for the future." Kiran Mazumdar Shaw at #BTS2024 #BTSUnbound
-
Biocon reposted this
"#ArtificialIntelligence operates as an iterative large-language model, drawing from existing knowledge and data. In contrast, living systems rely not only on existing and iterative data but also on genetic intelligence—an innate, intuitive form of intelligence encoded in their DNA. This presents two distinct realms of intelligence: artificial and genetic. It's here that our focus must shift, as biology holds immense untapped potential. While we are firmly in the digital age today, the future lies in the realm of bioengineering, where biology and technology converge to shape transformative solutions." Kiran Mazumdar Shaw on power of #AI at #BTS2024 #BTSUnbound
-
"#ArtificialIntelligence operates as an iterative large-language model, drawing from existing knowledge and data. In contrast, living systems rely not only on existing and iterative data but also on genetic intelligence—an innate, intuitive form of intelligence encoded in their DNA. This presents two distinct realms of intelligence: artificial and genetic. It's here that our focus must shift, as biology holds immense untapped potential. While we are firmly in the digital age today, the future lies in the realm of bioengineering, where biology and technology converge to shape transformative solutions." Kiran Mazumdar Shaw on power of #AI at #BTS2024 #BTSUnbound
-
"From the Digital Age today, we will be entering the Bioengineering Age tomorrow. Advanced data analytics, allows us to sort, segregate, analyse, and annotate vast amounts of biological data to deliver transformative solutions. This is the marvel of technology-driven biology. By unlocking its potential, we can tackle some of the world’s most pressing and unresolved challenges." Kiran Mazumdar Shaw at #BTSUnbound #BTS2024 Bengaluru Tech Summit
-
"I am very excited about the recently launched #BioE3 policy, which emphasizes the three pillars of ‘Environment, Economy, and Employment’. Built on the synergy between biology and technology, this policy positions Karnataka, and especially Bengaluru, with its thriving ecosystem of startups, at the forefront of the BioE3 revolution. Bio-manufacturing holds the potential to address numerous challenges we face today, and I firmly believe it represents the future of sustainable innovation." Kiran Mazumdar Shaw at the inaugural panel discussion on FutureScape: Redefining What’s Next at #BTS2024 #BTSUnbound
-
Global Capability Centres (GCC) Policy 2024–2029, launched at #BTSUnbound, targets 500 new centres by 2029. This makes #Karnataka the first state in the country to launch a dedicated GCC policy to attract investments in the growing sector. #BTS2024
-
The much-anticipated Bengaluru Tech Summit kicks off today in #Bengaluru! Kiran Mazumdar Shaw joins Hon’ble CM of Karnataka Shri Siddaramaiah, Hon’ble Dy. CM Shri D K Shivakumar & Minister for Electronics, IT/BT, and Rural Development & Panchayat Raj Shri Priyank M Kharge, along with other distinguished dignitaries, to inaugurate the #BengaluruTechSummit2024 - celebrating innovation, technology, & progress. #BTSUnbound
-
Biocon is proud to be Biotech Partner at the 27th Edition of the Bengaluru Tech Summit (BTS) Join us at Booth C18 from Nov 19-21 to explore ground breaking advancements in #biotech. For more details visit: https://lnkd.in/g9SUcGXj Let's shape the future of innovation together! #BangaloreTechSummit #Biocon #BTS2024